Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

The agreement is seen as a win for global health ahead of the US withdrawal from the WHO and amidst foreign aid cuts by the ...

US President Donald Trump has stated that the country is set to announce “major tariffs” on pharmaceutical imports very soon.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

The clinical trial (NCT04079166) is part of the NHS Cancer Vaccine Launch Pad (CVLP), a framework launched in May 2024 to ...

Leveraging Trump’s impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...